The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | CONKO-007: chemoradiotherapy increases rates of R0 resection in locally advanced pancreatic cancer
Rainer Fietkau, MD, PhD, University Hospital Erlangen, Erlangen, Germany, discusses the Phase III CONKO-007 trial (NCT01827553) trial designed to compare chemoradiotherapy (CRT) versus chemotherapy for patients with unresectable, locally advanced pancreatic cancer who had already received induction chemotherapy. No significant differences were observed in progression-free survival (PFS) or overall-survival (OS) between those receiving CRT and chemotherapy. However, in patients who underwent resection, R0 resections were significantly higher for patients receiving CRT than chemotherapy alone. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
